i-Port Advance system lowers blood sugar, hypoglycemic episodes in T1 diabetes: Study
Saudi Arabia: The use of i-Port Advance system may lower both blood sugar levels, hypoglycemic episodes, and raise patients' satisfaction levels in type 1 diabetes (T1D) patients, according to a recent study in the journal Diabetes & Metabolic Syndrome: Clinical Research & Reviews.Ayman A. Al Hayek, Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince...
Saudi Arabia: The use of i-Port Advance system may lower both blood sugar levels, hypoglycemic episodes, and raise patients' satisfaction levels in type 1 diabetes (T1D) patients, according to a recent study in the journal Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
Ayman A. Al Hayek, Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, and colleagues aimed to determine the efficacy of i-Port Advance system on patient satisfaction and glycemic control among patients with type 1 diabetes.
For this purpose, the researchers performed a prospective study among 73 patients with T1D (13–29 years) at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. Demographic data were collected at baseline and clinical characteristics were collected at baseline and 12 weeks.
Patients' responses to Morisky Medication Adherence Scale (MMAS-8) and Insulin Delivery Satisfaction Survey (IDSS) were recorded at baseline and 12 weeks after initiating the i-Port Advance system.
Key findings of the study include:
- At 12 weeks, significant improvement was evident in the IDSS subscales, which comprises the IDSS effective, burdensome, and IDSS inconvenient, with the total baseline IDSS score being 2.6 ± 0.42, and at 12 weeks being 3.7 ± 0.72.
- The MMAS total score at baseline was 4.6 ± 1.2, and at 12 weeks, it increased to 6.4.
- HbA1c level was 8.4% at baseline and decreased to 7.9% at 12 weeks. The total daily dose of insulin at baseline registered 0.9 ± 0.13, which declined to 0.8 ± 0.12 at 12 weeks.
- Fasting blood sugar value was 197 ± 23.4 at baseline, which dropped to 182 ± 24.5 at 12 weeks; and the postprandial glucose at baseline was 195 ± 21.4 and declined to 177 ± 19.2 at 12 weeks.
- The hypoglycemic episodes revealed a noteworthy reduction after the i-Port Advance system usage.
"Use of i-Port Advance system was found to raise the patients' satisfaction levels and lower both the hypoglycemic episodes as well as the HbA1c levels," wrote the authors.
Reference:
The study titled, "Efficacy of i-Port Advance system on patients satisfaction and glycemic control among patients with type 1 diabetes in Saudi Arabia," is published in the journal Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
DOI: https://www.sciencedirect.com/science/article/abs/pii/S1871402121001028
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd